Plain-English translation of ·
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new imaging scan called CAIX-targeted PET imaging that may help doctors detect kidney cancer more accurately. The scan works by targeting a protein called CAIX, which is found in very high levels in kidney cancer cells but rarely appears in healthy tissue. Researchers hope this specialized scan will help catch kidney cancer earlier and improve how well doctors can diagnose and stage the disease.
Kidney cancer is becoming more common, and early detection is crucial for better outcomes. Currently, doctors lack highly specific imaging tools designed to target kidney cancer cells early on, so this trial aims to see if this new imaging approach can fill that gap.
You likely qualify if…
You likely don't qualify if…
As a participant, you will undergo the new CAIX-targeted PET imaging scan, which is similar to a standard PET scan but uses a specialized tracer designed to find kidney cancer cells. The scan itself takes about 30 minutes and involves lying still in the imaging machine. You will also have blood tests to ensure your liver, kidney, and blood cell function are healthy enough to participate. The study team will compare the results of this new scan with your biopsy or surgery results to see how accurate the imaging is.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China